Analysis of Ofev (Nintedaninb) as IPF Therapy Shows Its Effectiveness in Range of Patients with Lung Disease
OFEV (nintedanib) is effective for a wide range of idiopathic pulmonary fibrosis (IPF) patients according to Boehringer Ingelheim, the company that developed the drug.